ClinicalTrials.gov
ClinicalTrials.gov Menu

Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01519349
Recruitment Status : Completed
First Posted : January 26, 2012
Last Update Posted : November 24, 2017
Sponsor:
Collaborators:
Parent Project Muscular Dystrophy
The Myositis Association (Grant Sponsor)
Information provided by (Responsible Party):
Jerry R. Mendell, Nationwide Children's Hospital

January 23, 2012
January 26, 2012
November 24, 2017
January 2012
October 2017   (Final data collection date for primary outcome measure)
Safety [ Time Frame: 2 years ]
Safety trial based on development of unacceptable toxicity defined as the occurrence of any Grade III or higher treatment-related toxicities.
Same as current
Complete list of historical versions of study NCT01519349 on ClinicalTrials.gov Archive Site
Muscle Function and Strength Testing [ Time Frame: 2 years ]
  • Muscle function and strength:
  • MRI of quadriceps muscles (bilateral)
  • Muscle biopsies on quadriceps muscles (a muscle biopsy on one leg at baseline screening visit - except for cohort 1 - and the post gene transfer biopsy on the opposite leg at day 180)
  • Thigh circumference measurement at baseline and post-gene transfer follow up visits up to day 180 (prior to second biopsy)
Same as current
Not Provided
Not Provided
 
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis.

The investigators are performing a gene therapy clinical trial in Becker muscular dystrophy (BMD) and sporadic inclusion body myositis (sIBM) patients. Both of these conditions have an important common feature: loss of ability to walk because of weakness of the thigh muscles. The investigators plan to do a gene therapy trial to deliver a gene to muscle called follistatin (FS344) that can build muscle size and strength. If successful, the investigators can increase the size of the thigh muscle and potentially prolong a patient's ability to walk. The gene will be carried into the muscle by a virus called adeno-associated virus (AAV). This virus occurs naturally in muscle and does not cause any human disease, setting the stage for its safe use in a clinical trial.

Presently there is no treatment that can reverse Becker muscular dystrophy or sporadic inclusion body myositis. Only supportive care is currently possible.

In this study, subjects with either of these diseases will have shots of the follistatin gene injected directly into thigh muscle on one (first cohort) or both legs (2nd and 3rd cohort). One hundred and eighty days following the gene delivery, the muscle will undergo biopsy to look closely at the muscle to see if the muscle fibers are bigger. Between the time of the gene transfer and the muscle biopsy, patients will be carefully monitored for any side effects of the treatment. This will include an MRI of the thigh muscle before treatment and at day 180 following treatment. Blood and urine tests, as well as physical examination will be done on the subjects during the screening visit and on days 0, 1, 2, 7, 14, 30, 60, 90, and 180 to make sure that there are no side effects from the gene injections. Sutures will be removed 2 weeks post-biopsy.

Additional blood samples will be collected at 9, 12, 18, and 24 months. Patients will be seen at the end of 1st and 2nd years for a physical exam, assessment of muscle strength and appropriate blood tests.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
  • Becker Muscular Dystrophy
  • Sporadic Inclusion Body Myositis
Biological: rAAV1.CMV.huFollistatin344
  • First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)
  • Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)
  • Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)
  • Experimental: Cohort 1
    Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)
    Intervention: Biological: rAAV1.CMV.huFollistatin344
  • Experimental: Cohort 2
    Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
    Intervention: Biological: rAAV1.CMV.huFollistatin344
  • Experimental: Cohort 3
    Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
    Intervention: Biological: rAAV1.CMV.huFollistatin344

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
Same as current
October 2017
October 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All subjects [sIBM and BMD must be ambulatory and have identifiable atrophy of the quadriceps muscle with muscle weakness ≥2 standard deviations below predicted using quantitative muscle testing (maximum voluntary isometric strength testing), and difficulty getting out of chairs, climbing stairs, and getting up from the floor.
  • sIBM patients include males and post-menopause females of any ethnic or racial group. Diagnosis of sIBM is based on previously published criteria that include distribution of weakness (knee extensor weakness, finger flexor weakness) and histological presence of inflammation and vacuolar myopathy. Patients with inflammation, vacuolar changes and intracellular amyloid deposits or 15/18nm filaments fulfill criteria irrespective of clinical features.
  • BMD patients include adult males (>18yo) of any ethnic or racial group with proven mutation of dystrophin gene and continued ambulation after age 15 years old.
  • Ability to cooperate for muscle testing
  • Deficit in muscle strength greater than 2 standard deviation below age expectations
  • Willingness of sexually active subjects with reproductive capacity (only male population) to practice reliable method of contraception until two negative sperm samples are obtained post gene transfer

Exclusion Criteria:

  • Active viral infection
  • History or evidence of active infection with hepatitis C, hepatitis A or B, or HIV
  • Patients with any other cause of muscle weakness based on medical history and screening physical exam including: myopathy (other dystrophies, polymyositis, and dermatomyositis), neuropathy (from any cause), myasthenia gravis, and weakness related to degenerative joint disease of the spine.
  • Ongoing immunosuppressive therapy or immunosuppressive therapy within 3 months of starting the trial (e.g. corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin, rituximab)
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer. Patients taking any of the following drugs will be excluded: drugs for treatment of myopathy or neuropathy or agents used to treat diabetes mellitus
  • Knee or ankle contractures preventing proper muscle strength testing
  • Patients with AAV1 neutralizing antibody titers ≥ 1:1600 as determined by ELISA immunoassay
  • Patients with history of angina and patients with past history of myocardial infarction in the past 6 months
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01519349
NCH-696110
Yes
Not Provided
Not Provided
Jerry R. Mendell, Nationwide Children's Hospital
Nationwide Children's Hospital
  • Parent Project Muscular Dystrophy
  • The Myositis Association (Grant Sponsor)
Principal Investigator: Jerry R Mendell, M.D. Nationwide Children's Hospital
Nationwide Children's Hospital
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP